Literature DB >> 462367

Timolol plus maximum tolerated antiglaucoma therapy: a one-year followup study.

F S Ashburn, J E Gillespie, M A Kass, B Becker.   

Abstract

Thirty-three eyes of 22 patients with primary open-angle glaucoma or severe ocular hypertension had topical timolol maleate added to their maximally tolerated medical regimens. With minimal side effects, 25 eyes (76%) could be treated medically for one year, and only eight eyes (24%) required filtering surgery. Thirteen (39%) of the medically treated eyes achieved intraocular pressures of 21 mm Hg or less. After the addition of timolol, 17 of the 33 eyes (52%) completed the one-year protocol with final mean intraocular pressure decreases of 5 mm Hg or more on medical therapy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 462367     DOI: 10.1016/0039-6257(79)90233-9

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  5 in total

1.  Effects of timolol on corneal sensitivity and tear production.

Authors:  Y Kitazawa; H Tsuchisaka
Journal:  Int Ophthalmol       Date:  1980-12       Impact factor: 2.031

Review 2.  Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.

Authors:  A M Brooks; W E Gillies
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

3.  The influence of long-term treatment with timolol on human tear lysozyme albumin content.

Authors:  G Strasser; G Grabner
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

4.  The IOP-lowering effect of timolol in simple and capsular glaucoma. A multicenter study in Finland.

Authors:  K K Takki; A Klemetti; O Valle
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1982       Impact factor: 3.117

5.  Study of the additive effect of timolol and epinephrine in lowering intraocular pressure.

Authors:  J V Thomas; D L Epstein
Journal:  Br J Ophthalmol       Date:  1981-09       Impact factor: 4.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.